Bidding War For Pliva Heats Up; Barr Edges Out $2.3 Bil. Offer From Actavis
This article was originally published in The Pink Sheet Daily
Executive Summary
Pliva recommends that shareholders take no action until antitrust issues are cleared.
You may also be interested in...
Actavis Raises Bid For Pliva; Will Barr Follow?
Actavis has increased its bid for the Croatian generic drug maker to roughly $2.5 bil., trumping Barr's $2.3 bil. offer.
Actavis Raises Bid For Pliva; Will Barr Follow?
Actavis has increased its bid for the Croatian generic drug maker to roughly $2.5 bil., trumping Barr's $2.3 bil. offer.
Two Pliva ANDAs Approved Following Lifting of FDA Hold
The Croatian firm will launch generic azithromycin imminently, having resolved manufacturing issues at its Zagreb plant.